Why the study?
Does an ACE inhibitor-based regimen reduce mortality and cardiovascular events in patients with vascular disease?
Population
Patients with a wide spectrum of vascular diseases, n > 29,000
Design
Editorial
Authors
Loading...
This editorial reinforces the use of ACE inhibitors at target doses to improve cardiovascular outcomes in patients with vascular disease, independent of the presence of hypertension.
Does an ACE inhibitor-based regimen reduce mortality and cardiovascular events in patients with vascular disease?
This editorial reinforces the use of ACE inhibitors at target doses to improve cardiovascular outcomes in patients with vascular disease, independent of the presence of hypertension.
Bertram Pitt (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: